---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-25-009701"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2025-08-01T23:59:59+00:00"
generated_at: "2026-05-17T21:53:04.490280+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Amneal completes $2.7B refinancing: $2.1B term loan and $600M notes

## Summary
- Borrowed $2.1B of new seven-year term B loans due Aug 2032; margin SOFR+3.50% or base+2.50%.
- Issued $600M 6.875% senior secured notes due Aug 2032; proceeds used to refinance existing debt.
- Amended ABL facility extends maturity to Aug 2030; $600M revolving commitments unchanged.
- Refinanced existing $2.26B term loans in full and repaid all ABL borrowings with net proceeds.

## SEC filing metadata
- accession: 0000950103-25-009701
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2025-08-01T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000095010325009701/0000950103-25-009701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000095010325009701/dp232462_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-25-009701
- JSON: https://secwatch.observer/filing/0000950103-25-009701.json
- Plain text: https://secwatch.observer/filing/0000950103-25-009701.txt

## Key facts
- Debt Financings
  Amneal Pharmaceuticals, Inc. incurred senior notes of $600 million aggregate principal amount with Wilmington Savings Fund Society, FSB, as trustee and collateral agent at 6.875% maturing August 1, 2032.
  - Instrument: senior notes
  - Principal: $600 million aggregate principal amount
  - Counterparty: Wilmington Savings Fund Society, FSB, as trustee and collateral agent
  - Rate: 6.875%
  - Maturity: August 1, 2032
  - Event: incurrence
  source text: completed the previously announced offering of $600 million aggregate principal amount of 6.875% senior secured notes due 2032 (the “Notes”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000095010325009701/0000950103-25-009701-index.htm
- Debt Financings
  Amneal Pharmaceuticals, Inc. incurred term loan of $2.1 billion with JPMorgan Chase Bank, N.A., as administrative agent at term SOFR benchmark rate or the base rate, plus an applicable margin, ... subjec maturing August 1, 2032.
  - Instrument: term loan
  - Principal: $2.1 billion
  - Counterparty: JPMorgan Chase Bank, N.A., as administrative agent
  - Rate: term SOFR benchmark rate or the base rate, plus an applicable margin, ... subjec
  - Maturity: August 1, 2032
  - Event: incurrence
  source text: On August 1, 2025, Amneal Pharmaceuticals, Inc.’s (the “Corporation”) subsidiary, Amneal Pharmaceuticals LLC (the “Company” or, the “Issuer”) borrowed $2.1 billion of new seven-year term B loans (the “New Term Loan”) pursuant to an amendment to the Company’s existing term loan credit facility
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000095010325009701/0000950103-25-009701-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.